A Critical Review on Chagas Disease Chemotherapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Andrade AL, 1996, Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection, Lancet, 348, 1407, 10.1016/S0140-6736(96)04128-1
Andrade SG, 1977, Estudo experimental sobre a ação terapêutica da droga RO 7 - 1051 na infecção por diferentes cepas do Trypanosoma cruzi, Rev Inst Med Trop São Paulo, 19, 335
Andrade SG, 1977, Estudo experimental sobre a resistência de uma cepa ao Bay 2502, Rev Inst Med Trop São Paulo, 19, 124
Andrade SG, 1989, Treatment of chronic experimental Trypanosoma cruzi infections in mice with MK-436, a 2-substituted 5-nitroimidazole, Bull WHO, 67, 509
Andrade SG, 1975, Reaction of the Trypanosoma cruzi strain to the experimental therapeutical response to Bay 2502 (results of long term treatment), Rev Inst Med Trop São Paulo, 17, 380
Andrade SG, 1991, Experimental chemotherapy of Trypanosoma cruzi infection persistence of parasite antigens and positive sorology in parasitologically cured mice, Bull WHO, 69, 191
Andrade SG, 2000, Interstitial dendritic cells of the heart harbor Trypanosoma cruzi antigens in experimentally infected dogs: importance for the pathogenesis of chagasic myocarditis, Am J Trop Med Hyg, 63, 64, 10.4269/ajtmh.2000.63.64
Andrade ZA, 1999, Immunopathology of Chagas disease, Mem Inst Oswaldo Cruz, 94, 71, 10.1590/S0074-02761999000700007
Anez N, 1999, Myocardial parasite persistence in chronic chagasic patients, Am J Trop Med Hyg, 60, 726, 10.4269/ajtmh.1999.60.726
Apt W, 1998, Treatment of chronic Chagas disease with itraconazole and allopurinol, Am J Trop Med Hyg, 59, 133, 10.4269/ajtmh.1998.59.133
Araújo MS, 2000, A combination of benznidazole and ketoconazole enhances efficacy of chemotherapy of experimental Chagas disease, J Antimicrob Chemother, 45, 819, 10.1093/jac/45.6.819
Augustyns K, 2001, Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents, Curr Pharm Des, 7, 1117, 10.2174/1381612013397564
Ávila H, 1991, Polymerase chain reaction amplification of Trypanosoma cruzi kinetoplast minicircle DNA isolated from whole blood lysates: diagnosis of chronic Chagas disease, Mol Biochem Parasitol, 48, 211, 10.1016/0166-6851(91)90116-N
Bankova VS, 2000, Propolis: recent advances in research on chemistry and plant origin, Apidologie, 31, 3, 10.1051/apido:2000102
Bastos JK, 1999, Evaluation of the trypanocidal activity of lignans isolated from the leaves of Zanthoxylum naranjillo, Planta Med, 65, 541, 10.1055/s-1999-14012
Batista R, 1999, Trypanosomicidal kaurane diterpenes from Wedelia paludosa, Planta Med, 65, 283, 10.1055/s-2006-960781
Berger I, 2001, Antiprotozoal activity of Neurolaena lobata, Phytother Res, 15, 327, 10.1002/ptr.782
Bocca-Tourres LC, 1969, La enfermedad de Chagas en período agudo y su tratamiento con el Bay 2502, Bol Chil Parasitol, 24, 24
Bock M, 1969, Studies with Bay 2502 on animals, Bol Chil Parasitol, 24, 13
Bodley AL, 1995, 3726
Boechat N, 2001, Novel nitroimidazoles with trypanocidal and cell growth inhibition activities, Cytobios, 105, 83
Bogitsh BJ, 1999, Effects of the antitubulin drug trifluralin on the proliferation and metacyclogenesis of Trypanosoma cruzi epimastigotes, Parasitol Res, 85, 475, 10.1007/s004360050580
Bonay P, 1998, Antiparasitic effects of the intra-Golgi transport inhibitor megalomicin, Antimicrob Agents Chemother, 42, 2668, 10.1128/AAC.42.10.2668
Bonnet B, 1997, New spermine and spermidine derivatives as potent inhibitors of Trypanosoma cruzi trypanothione reductase, Bioorg Med Chem, 5, 1249, 10.1016/S0968-0896(97)00070-9
Bonse S, 2000, (2,2':6',2"-Terpyridine)platinum(II) complexes are irreversible inhibitors of Trypanosoma cruzi trypanothione reductase but not of human glutathione reductase, J Med Chem, 43, 4812, 10.1021/jm000219o
Brener Z, 1961, Atividade terapêutica do 5-nitrofuraldeido- semicarbazona (nitrofurazona) em esquemas de duração prolongada na infecção experimental pelo Trypanosoma cruzi, Rev Inst Med Trop São Paulo, 3, 43
Brener Z, 1968, Terapêutica experimental da doença de Chagas, 510
Brener Z, 1975, Chemotherapy of Trypanosoma cruzi infection, Adv Pharmacol Chemother, 13, 1, 10.1016/S1054-3589(08)60229-X
Brener Z, 1979, Present status of chemotherapy and chemoprofilaxis of human trypanosomiasis in the Western hemisphere, PharmacTherap, 7, 71
Brener Z, 1984, Recent advances in chemotherapy of Chagas disease, Mem Inst Oswaldo Cruz, 79, 149, 10.1590/S0074-02761984000500026
Brener Z, 2000, Terapêutica experimental na doença de Chagas, 2, 379
Brener Z, 2000, 2ª
Brener Z, 1969, An electron microscope study on Trypanosoma cruzi intracellular forms in mice treated with active nitrofuran compound, Rev Inst Med Trop São Paulo, 11, 245
Brener Z, 1993, An experimental and clinical assay with ketoconazole in the treatment of Chagas disease, Mem Inst Oswaldo Cruz, 88, 149, 10.1590/S0074-02761993000100023
Brengio SD, 2000, The sesquiterpene lactone dehydroleucodine (DhL) affects the growth of cultured epimastigotes of Trypanosoma cruzi, J Parasitol, 86, 407, 10.1645/0022-3395(2000)086[0407:TSLDDA]2.0.CO;2
Bressi JC, 2001, Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of trypanosomatidae via structure-based drug design, J Med Chem, 44, 2080, 10.1021/jm000472o
Britto C, 1995, Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation, Parasitology, 110, 241, 10.1017/S0031182000080823
Britto C, 2001, Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction, Mem Inst Oswaldo Cruz, 96, 823, 10.1590/S0074-02762001000600014
Bronia DH, 1999, Ganglioside treatment of acute Trypanosoma cruzi infection in mice promotes long-term survival and parasitological cure, Ann Trop Med Parasitol, 93, 341, 10.1080/00034983.1999.11813430
Bsiri N, 1996, Trypanocidal structure-activity relationship in 9-thioalkylacridines, Ann Pharm Fr, 54, 27
Buckner FS, 2001, Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors, Antimicrob Agents Chemother, 45, 1210, 10.1128/AAC.45.4.1210-1215.2001
Buckner FS, 1998, Induction of resistance to azole drugs in Trypanosoma cruzi, Antimicrob Agents Chemother, 42, 3245, 10.1128/AAC.42.12.3245
Caceres A, 1998, Plants used in Guatemala for the treatment of protozoal infections: I. Screening of activity to bacteria, fungi and American trypanosomes of 13 native plants, J Ethnopharmacol, 62, 195, 10.1016/S0378-8741(98)00140-8
Camargo ME, 1966, Fluorescent antibody test for serodiagnosis of American Trypanosomiasis: Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test, Rev Inst Med Trop São Paulo, 8, 227
Cançado JR, 1963, Aspectos clínicos na padronização dos métodos de avaliação terapêutica na doença de Chagas, Rev Goiana Med, 9, 212
Cançado JR, 1968, Tratamento da doença de Chagas, 517
Cançado JR, 1981, 22
Cançado JR, 1985, Tratamento específico, 327
Cançado JR, 1997, Terapêutica específica, 323
Cançado JR, 1999, Criteria of Chagas disease cure, Mem Inst Oswaldo Cruz, 94, 331, 10.1590/S0074-02761999000700064
Cançado JR, 2000, Tratamento etiológico da doença de Chagas, 2, 389
Cançado JR, 1979, Terapêutica, 362
Cançado JR, 1964, Ensaio terapêutico clínico com a 5-nitro-2-furaldeido-semicarbazona (Nitrofurazona) na forma crônica da doença de Chagas, Rev Inst Med Trop São Paulo, 6, 12
Cançado JR, 1969, Toxicidade y valor terapêutico del Bay 2502 en la enfermedad de Chagas in tres esquemas posológicos, Bol Chil Parasitol, 24, 28
Cançado JR, 1973, Bases para avaliação do tratamento específico da doença de Chagas humana segundo a parasitemia, Rev Soc Bras Med Trop, 7, 155, 10.1590/S0037-86821973000300001
Cançado JR, 1975, Clinical therapeutic trial in chronic Chagas disease using nifurtimox in 3 schedules of long duration, Rev Inst Med Trop São Paulo, 17, 111
Cançado JR, 1976, Segundo ensaio terapêutico com nifurtimox na doença de Chagas, Rev Goiana Med, 22, 203
Castilla JJ, 1996, In vitro activity and biochemical effectiveness of new organometallic complexes of osmium(III) against Leishmania donovani and Trypanosoma cruzi, Arznein Forsch, 46, 990
Cazzulo JJ, 2001, The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease, Curr Pharm Des, 7, 1143, 10.2174/1381612013397528
Cerecetto H, 1999, 1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships, J Med Chem, 42, 1941, 10.1021/jm9805790
Cerecetto H, 2000, Synthesis and antitrypanosomal evaluation of E-isomers of 5-nitro-2-furaldehyde and 5-nitrothiophene-2-carboxaldehyde semicarbazone derivatives: Structure-activity relationships, Eur J Med Chem, 35, 343, 10.1016/S0223-5234(00)00131-8
Cerisola JA, 1972, Enfermedad de Chagas y la transfusión de sangue, Bol Of Sanit Panam, 73, 203
Cerisola JA, 1977, Evaluación mediante xenodiagnostico de la efectividad del nifurtimox en la infección chagásica crónica humana, Bol Chil Parasitol, 32, 51
Chagas C, 1935, I
Chan C, 1998, Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs, J Med Chem, 41, 148, 10.1021/jm960814j
Chataing B, 1998, Inhibition of Trypanosoma cruzi growth in vitro by Solanum alkaloids: a comparison with ketoconazole, Planta Med, 64, 31, 10.1055/s-2006-957361
Chiari E, 1966, Contribuição ao diagnóstico parasitológico da doença de Chagas na fase crônica, Rev Inst Med Trop São Paulo, 8, 134
Chiari E, 1989, Hemocultures for the parasitological diagnosis of human chronic Chagas disease, Rev Soc Bras Med Trop, 22, 19, 10.1590/S0037-86821989000100004
Chiari E, 1996, Potential use of WR6026 as prophylaxis against transfusion-transmitted American trypanosomiasis, Antimicrob Agents Chemother, 40, 613, 10.1128/AAC.40.3.613
Chowdhury SF, 2001, Novel inhibitors of leishmanial dihydrofolate reductase, Bioorg Med Chem Lett, 11, 977, 10.1016/S0960-894X(01)00089-0
Chung MC, 1997, Synthesis and in vitro evaluation of potential antichagasic dipeptide prodrugs of primaquine, J Pharm Sci, 86, 1127, 10.1021/js970006v
Cinque GM, 1998, Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi, J Med Chem, 41, 1540, 10.1021/jm970860z
Clark AM, 1996, Natural products as a resource for new drugs, Pharmaceutical Res, 13, 1133, 10.1023/A:1016091631721
Costa Silva R, 1990, Isoenzymatic pattern of Trypanosoma cruzi Y strain after specific chemotherapy, Mem Inst Oswaldo Cruz, 84, 81
Coura JR, 1996, Perspectivas actuales del trataamiento específico de la enfermedad de Chagas, Bol Chil Parasitol, 51, 69
Coura JR, 1961, Aspectos atuais do tratamento da doença de Chagas, Rev Bras Med, 51, 283
Coura JR, 1961, Tentativa terapêutica com a nitrofurazona (Furacin) na forma crônica da doença de Chagas, O Hospital, 60, 425
Coura JR, 1962, Experiências com nitrofurazona na fase crônica da doença de Chagas, O Hospital, 62, 957
Coura JR, 1978, 161
Coura JR, 1991, Evaluation of the xenodiagnosis of chronic Chagas patients infected ten years or over in an area where transmission has been interrupted-Iguatama and Pains, West Minas Gerais State, Brazil, Mem Inst Oswaldo Cruz, 86, 395, 10.1590/S0074-02761991000400003
Coura JR, 1997, Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas disease, in a field area with interrupted transmission: I. Preliminary evaluation, Rev Soc Bras Med Trop, 30, 139
Croft SL, 1994, A rationale for antiparasite drug discovery, Parasitol Today, 10, 385, 10.1016/0169-4758(94)90227-5
Croft SL, 1996, The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei, J Antimicrob Chemother, 38, 1041, 10.1093/jac/38.6.1041
Dantas AP, 2000
Dantas AP, 1998, Studies on the effect of dinitroaniline herbicides in Trypanosoma cruzi, Mem Inst Oswaldo Cruz, 93, 311
De Castro SL, 1993, The challenge of Chagas disease chemotherapy: an update of drugs assayed against Trypanosoma cruzi, Acta Trop, 53, 83, 10.1016/0001-706X(93)90021-3
De Castro, 2001, Propolis: Biological and pharmacological activities. Therapeutic uses of this bee-product, Ann Rev Biol Sci
De Castro SL, 1995, Effect of different formulations of propolis on mice infected with Trypanosoma cruzi, J Ethnopharmacol, 46, 55, 10.1016/0378-8741(95)01228-6
De Castro SL, 1994, Screening of natural and synthetic drugs against Trypanosoma cruzi: establishing a structure/activity relationship, Microbios, 78, 83
De Castro SL, 2001
De Conti R, 1996, In vitro trypanocidal activities of a novel series of N, N-dimethyl-2-propen-1-amine derivative, Microbios, 85, 83
De Moura KCG, 2001, Synthesis and trypanocidal activity of naphthoquinones isolated from Tabebuia and heterocyclic derivatives: a review from an interdisciplinary study, J Braz Chem Soc, 12, 325
Deharo E, 2000, Aminothiol multidentate chelators against Chagas disease, Exp Parasitol, 94, 198, 10.1006/expr.1999.4483
Di Maio R, 1999, Synthesis and antichagasic properties of new 1,2,6-thiadiazin-3, 5-dione 1,1-dioxides and related compounds, Arznein Forsch, 49, 759
Dias JCP, 2000, Epidemiologia, 2, 48
Diaz de Toranzo EG, 1988, Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi, Experientia, 44, 880, 10.1007/BF01941187
DoCampo R, 2001, Recent developments in the chemotherapy of Chagas disease, Curr Pharm Design, 7, 1157, 10.2174/1381612013397546
DoCampo R, 1986, Free radical metabolism of antiparasitic agents, Fed Proceed, 45, 2471
DoCampo R, 2001, Bisphosphonates as chemotherapeutic agents against trypanosomatids and Apicomplexan parasites, Current Drug Targets-Infectious Disorders, 1, 51, 10.2174/1568005013343191
Dubin M, 2001, Cytotoxicity of beta-lapachone, a naphthoquinone with possible therapeutic use, Medicina (B Aires), 61, 343
Eakin AE, 1997, Hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design: crystallization and inhibition studies with purine analogs, Antimicrob Agents Chemother, 41, 1686, 10.1128/AAC.41.8.1686
Engel JC, 1998, Cysteine protease inhibitors after Golgi complex ultrastructure and function in Trypanosoma cruzi, J Cell Sci, 111, 597, 10.1242/jcs.111.5.597
Engel JC, 1998, Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection, J Exp Med, 188, 725, 10.1084/jem.188.4.725
Fairlamb AH, 1999, Future prospects for the chemotherapy of Chagas disease, Medicina (B Aires), 59, 179
Fairlamb AH, 1992, Metabolism and functions of trypanothione in the kinetoplastida, Annu Rev Micorbiol, 46, 695, 10.1146/annurev.mi.46.100192.003403
Fernandez-Gomez R, 1994, Growth inhibition of Trypanosoma cruzi and Leishmania donovani infantum by different snake venoms: preliminary identification of proteins from Cerastes cerastes venom which interact with the parasites, Toxicon, 32, 875, 10.1016/0041-0101(94)90366-2
Ferreira HO, 1961, Forma aguda da doença de Chagas tratada pela nitrofurazona, Rev Inst Med Trop São Paulo, 3, 287
Ferreira HO, 1962, Fase aguda da doença de Chagas, O Hospital, 61, 307
Ferreira HO, 1976, Ensaio terapêutico-clínico com benznidazol na doença de Chagas, Rev Inst Med Trop São Paulo, 18, 357
Ferreira HO, 1990, Tratamento da forma indeterminada da doença de Chagas com nifurtimox e benznidazol, Rev Soc Bras Med Trop, 23, 209, 10.1590/S0037-86821990000400005
Ferreira HO, 1963, Administração prolongada de nitrofurazona no tratamento da doença de Chagas aguda, O Hospital, 63, 131
Ferreira MS, 1997, Doença de Chagas e imunossupressão, 365
Ferreira MS, 1997, Reactivation of Chagas disease in patients with AIDS: report of three new cases and review of the literature, Clin Infect Dis, 25, 1397, 10.1086/516130
Fichera L, 1995, Effects of juvenile hormone analogues (JHA) on the development of Trypanosoma cruzi, Z Naturforsch, 50C, 578, 10.1515/znc-1995-7-817
Fife Jr. EH, 1959, 540
Filardi LS, 1982, Nitroinidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infection, Ann Trop Med Parasitol, 76, 293, 10.1080/00034983.1982.11687544
Fournet A, 1994, Leishmanicidal and trypanocidal activities of Bolivian medicinal plants, J Ethnopharmacol, 41, 19, 10.1016/0378-8741(94)90054-X
Fournet A, 1998, Trypanocidal bisbenzylisoquinoline alkaloids are inhibitors of trypanothione reductase, J Enzym Inhib, 13, 1, 10.3109/14756369809035823
Fournet A, 2000, Efficacy of the biisbenziylisoquinoline alkaloids in acute and chronic Trypanosoma cruzi murine model, Int J Antimicrob Agents, 13, 189, 10.1016/S0924-8579(99)00117-X
Fragata Filho AA, 1995, Validade do tratamento etiológico da fase crônica da doença de Chagas com benznidazol, Arq Bras Cardiol, 65, 71
Fragoso SP, 1992, Cloning and characterization of the gene encoding Trypanosoma cruzi DNA topoisomerase II, Mol Biochem Parasitol, 55, 127, 10.1016/0166-6851(92)90133-5
Fragoso SP, 1998, Expression and cellular localization of Trypanosoma cruzi type II DNA topoisomerase, Mol Biochem Parasitol, 94, 197, 10.1016/S0166-6851(98)00066-8
Freitas JLP, 1949, Nova técnica de fixação de complemento para a moléstia de Chagas: (Reação quantitativa com antígeno geleificado de culturas de Trypanosoma cruzi), O Hospital, 35, 787
Freymann DM, 2000, Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi, Chem Biol, 7, 957, 10.1016/S1074-5521(00)00045-4
Galhardo MCG, 1999, Reactivação da infecção por Trypanosoma cruzi em paciente com síndrome de imunodeficiência adquirida, Rev Soc Bras Med Trop, 32, 291, 10.1590/S0037-86821999000300011
Galleano RH, 1990, Therapeutic efficacy of allopurinol in patients with chronic Chagas disease, Am J Trop Med Hyg, 43, 159, 10.4269/ajtmh.1990.43.159
Girault S, 1998, Structure-activity relationships in 2-aminodiphenylsulfides against trypanothione reductase from Trypanosoma cruzi, Bioorg Med Chem Lett, 8, 1175, 10.1016/S0960-894X(98)00180-2
Girault S, 2000, Antimalarial, antitrypanosomal, and antileishmanial activities and cytotoxicity of bis(9-amino-6-chloro-2-methoxyacridines): influence of the linker, J Med Chem, 43, 2646, 10.1021/jm990946n
Gonzales-Perdomo M, 1990, Trypanosoma cruzi proliferation and differentiation are blocked by topoisomerase II inhibitors, Antimicrob Agents Chemother, 34, 1707, 10.1128/AAC.34.9.1707
Gonzalez-Martin G, 2000, Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity, Eur J Pharm Biopharm, 49, 137, 10.1016/S0939-6411(99)00076-4
Gonzalez-Martin G, 1998, Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates, J Pharm Pharmacol, 50, 29, 10.1111/j.2042-7158.1998.tb03301.x
Grellier P, 1999, Selective and reversible effects of Vinca alkaloids on Trypanosoma cruzi epimastigote forms: blockage of cytokinesis without inhibition of the organelle duplication, Cell Motil Cytoskeleton, 42, 36, 10.1002/(SICI)1097-0169(1999)42:1<36::AID-CM4>3.0.CO;2-G
Guerreiro C, 1913, Da reação de Bordet e Gengou na moléstia de Carlos Chagas como elemento de diagnóstico, Brasil Med, 27, 225
Gutierrez-Correa J, 2001, Trypanosoma cruzi trypanothione reductase is inactivated by peroxidase-generated phenothiazine cationic radicals, Free Radic Res, 34, 363, 10.1080/10715760100300311
Henderson GB, 1988, 5374
Higashi KO, 1994, Propolis extracts are effective against Trypanosoma cruzi and have an impact on its interaction with host cells, J Ethnopharmacol, 43, 149, 10.1016/0378-8741(94)90012-4
Higuchi ML, 1999, Human chagasic cardiopathy: participation of parasite antigens, subsets lymiphocytes, cytokines and microvascular abnormalities, Mem Inst Oswaldo Cruz, 94, 263, 10.1590/S0074-02761999000700044
Higuchi ML, 1993, Correlation between Trypanosoma cruzi parasitism and myocardial inflammation in human chronic chagasic myocardits: Light microscopy and immunohistochemical findings, Cardiovasc Pathol, 2, 101, 10.1016/1054-8807(93)90021-S
Higuchi ML, 1997, Human chronic chagasic myocarditis is Trypanosoma cruzi antigen and CD8+ T cell dependent, Am J Trop Med Hyg, 56, 485, 10.4269/ajtmh.1997.56.485
Hoare CA, 1966, Developmental stages of trypanosomatid flagellates: a new terminology, Nature, 244, 69
Hoffmann BK, 1972, Toxicological investigations on the tolerability of nifurtimox, Arzeneim Forsch, 22, 1590
Ianni BM, 1993, Uso de benznidazol em chagásicos na forma indeterminada: Resultados a longo prazo, Arq Bras Cardiol, 61, 130
Jatene AD, 1997, Tratamento cirúrgico da cardiopatia chagásica, 255
Jones EM, 1993, Amplification of Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy, Am J Trop Med Hyg, 48, 348, 10.4269/ajtmh.1993.48.348
Junqueira ACV, 1996, Comparison of the polymerase chain reaction with two classical parasitological methods, for diagnosis of Chagas disease in endemic region of North-Eastern Brazil, Trans R Soc Trop Med Hyg, 90, 129, 10.1016/S0035-9203(96)90111-X
Kelser RA, 1936, A complement fixation test for Chagas disease employing an artificial culture antigen, Am J Trop Med Hyg, 16, 405, 10.4269/ajtmh.1936.s1-16.405
Kerschmann RL, 1989, Novobiocin-induced ultrastructural changes and antagonism of DNA synthesis in Trypanosoma cruzi amastigotes growing in cell-free medium, J Protozool, 36, 14, 10.1111/j.1550-7408.1989.tb02669.x
Kinnamon KE, 1996, Primaquine analogues that are potent anti-Trypanosoma cruzi agents in a mouse model, Ann Trop Med Parasitol, 90, 467, 10.1080/00034983.1996.11813071
Kinnamon KE, 1997, Evidence that certain 8-aminoquinolines are potentially effective drugs against Chagas disease, Ann Trop Med Parasitol, 91, 147, 10.1080/00034983.1997.11813124
Krauth-Siegel RL, 1987, Trypanothione reductase from Trypanosoma cruzi: Purification and characterization of the crystalline enzyme, Eur J Biochem, 164, 123, 10.1111/j.1432-1033.1987.tb11002.x
Krettli AU, 1982, Resistance against Trypanosoma cruzi associate to anti-living trypomastigote antibodies, J Immunol, 128, 2009, 10.4049/jimmunol.128.5.2009
Krettli AU, 1984, Criterion of cure of human Chagas disease after especific treatment: recent advances, Mem Inst Oswaldo Cruz 79, (Suppl), 157, 10.1590/S0074-02761984000500027
Lalmanach G, 1996, Biotin-labelled peptidyl diazomethane inhibitors derived from the substrate-like sequence of cystatin: targeting of the active site of cruzipain, the major cysteine proteinase of Trypanosoma cruzi, Biochem J, 318, 395, 10.1042/bj3180395
Lane JE, 1996, In vitro trypanocidal activity of tetraethylthiuram disulfide and sodium diethylamine-N-carbodithioate on Trypanosoma cruzi, Am J Trop Med Hyg, 55, 263, 10.4269/ajtmh.1996.55.263
Lane JE, 1998, Ultrastructural effects of the chelating agent 1,10-phenanthroline on Trypanosoma cruzi epimastigotes in vitro, Parasitol Res, 84, 399, 10.1007/s004360050417
Lauria-Pires L, 1988, Ineficácia do allopurinol em pacientes na fase aguda da doença de Chagas, Rev Soc Med Trop, 21, 79, 10.1590/S0037-86821988000200011
Lazzari JO, 1998, Tratamiento de la enfermedad de Chagas crónica en Argentina, Rev Patol Trop, 27, 11
Li Z, 2001, Polyamines with N-(3-phenylpropyl) substituents are effective competitive inhibitors of trypanothione reductase and trypanocidal agents, Bioorg Med Chem Lett, 11, 251, 10.1016/S0960-894X(00)00643-0
Lira R, 2001, Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole, J Antimicrob Chemother, 47, 537, 10.1093/jac/47.5.537
Lopes JN, 1978, In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi, Ann Trop Med Parasitol, 72, 523, 10.1080/00034983.1978.11719356
Lujan HD, 1993, Effect of gangliosides on Trypanosoma cruzi infection in mice, Life Sci, 53, PL69, 10.1016/0024-3205(93)90651-I
Luque F, 2000, In vitro evaluation of newly synthesized [1,2,4]triazolo[1, 5a]pyrimidine derivatives against Trypanosoma cruzi, Leishmania donovani and Phytomonas staheli, Comp Biochem Physiol C Toxicol Pharmacol, 126, 39
Luquetti, 1997, Etiological treatment for Chagas disease: The National Health Foundation of Brazil, Parasitol Today, 13, 127, 10.1016/S0169-4758(97)01018-1
Luz ZMP, 1994, Hemocultura: técnica sensível na detecção do Trypanosoma cruzi em pacientes chagásicos crônicos, Rev Soc Bras Med Trop, 27, 143, 10.1590/S0037-86821994000300004
Macêdo VO, 1997, Forma indeterminada da doença de Chagas, 383
Macêdo VO, 1987, Perspectivas da terapêutica específica na doença de Chagas: Experiências na forma indeterminada, Rev Soc Bras Med Trop, 20, M24
Mafezoli J, 2000, In vitro activity of Rutaceae species against the trypomastigote form of Trypanosoma cruzi, J Ethnopharmacol, 73, 335, 10.1016/S0378-8741(00)00315-9
Mahiou V, 2000, Bisbenzylisoquinoline alkaloids from Guatteria boliviana (Annonaceae), Phytochemistry, 54, 709, 10.1016/S0031-9422(00)00178-3
Marcucci MC, 2001, Phenolic compounds from Brazilian propolis with pharmacological activities, J Ethnopharmacol, 74, 105, 10.1016/S0378-8741(00)00326-3
Marr JJ, 1991, Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis, J Lab Clin Med, 118, 111
Martin MB, 2001, Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy, J Med Chem, 44, 909, 10.1021/jm0002578
Maya JD, 2000, Effects of 3-chloro-phenyl-1,4-dihydropyridine derivatives on Trypanosoma cruzi epimastigotes, Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 125, 103, 10.1016/S0742-8413(99)00096-1
Mayer M, 1912, Zur Entwicklung von Schizotrypanum cruzi in Saengatieren, Arch Schisffs u Tropen Hyg, 16, 90
Mayer M, 1914, Zum Verhalten von Schizotrypanum cruzi in Warmbluetern und Arthropoden, Arch Schiffs u Tropen-Hyg, 5, 101
Mazza S, 1937, Primer caso agudo de enfermedad de Chagas, comprovado em Tucuman y su tratamiento com Bayer 7602, Mis Estudios Patolog Reg Argentina, 32, 3
Mazza S, 1942, Ensayos terapéuticos del produto 9736 (As) Bayer y de su acción comparada en el 7602 (Ac) Bayer en la enfermedad de Chagas, Mis Estudios Patolog Reg Argentina, 61, 1
McKerrow JH, 1999, Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: Insights on safety, target validation, and mechanism of action, Int J Parasitol, 29, 833, 10.1016/S0020-7519(99)00044-2
Medrano NM, 1996, Acute Chagas disease: Plasma levels of alpha-2-macroglobulin and C-reactive protein in children under 13 years in a high endemic area of Bolivia, J Trop Pediatr, 42, 68, 10.1093/tropej/42.2.68
Molina J, 2000, Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts, Antimicrob Agents Chemother, 44, 150, 10.1128/AAC.44.1.150-155.2000
Molina J, 2001, Cure of experimental Chagas disease by the bis-triazole DO870 incorporated into "stealth" polyethyleneglycol-polylactide nanospheres, J Antimicrob Chemother, 47, 101, 10.1093/jac/47.1.101
Montalvetti A, 2001, Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase, J Biol Chem, 276, 33930, 10.1074/jbc.M103950200
Morello A, 1994, Trypanocidal effect of boldine and related alkaloids upon several strains of Trypanosoma cruzi, Comp Biochem Physiol Pharmacol Toxicol Endocrinol, 107, 367, 10.1016/1367-8280(94)90063-9
Morello A, 1995, Effects and mode of action of 1,4-naphthoquinones isolated from Calceolaria sessilis on tumoral cells and Trypanosoma parasites, Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 112, 119, 10.1016/0742-8413(95)02003-9
Moser DR, 1989, Detection of Trypanosoma cruzi by DNA amplification using the polymerase chain reaction, J Clin Microbiol, 27, 1477, 10.1128/JCM.27.7.1477-1482.1989
Muelas S, 2001, New thiadiazine derivatives with activity against Trypanosoma cruzi amastigotes, Folia Parasitol (Praha), 48, 105, 10.14411/fp.2001.015
Muelas-Serrano S, 2000, In vitro screening of American plant extracts on Trypanosoma cruzi and Trichomonas vaginalis, J Ethnopharmacol, 71, 101, 10.1016/S0378-8741(99)00185-3
Nakajima-Shimada J, 1996, Inhibition of Trypanosoma cruzi growth in mammalian cells by purine and pyrimidine analogs, Antimicrob Agents Chemother., 40, 2455, 10.1128/AAC.40.11.2455
Neal RA, 1970, Indirect hemaglutination test for Chagas disease, with a simple method for survey work, Rev Inst Med Trop São Paulo, 12, 325
Neira I, 1998, Activity of Dipernoids isolated from Azorella compacta (Llareta) on Trypanosoma cruzi amastigotes, Bol Chil Parasitol, 53, 9
Neves-Pinto C, 2000, Chemical reactivity studies with naphthoquinones from Tabebuia with anti-trypanosomal efficacy, Arzneim Forsch, 50, 1120
Nunez-Vergara LJ, 1997, Nitro aryl 1,4-dihydropyridine derivatives: effects on Trypanosoma cruzi, Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 118, 105, 10.1016/S0742-8413(97)00078-9
Nussenzweig V, 1953, Ação da violeta de genciana sobre o T. cruzi in vitro: sua importância na esterilização do sangue destinado à transfusão, Rev Paul Med, 42, 57
Ochoa C, 1999, Synthesis and antiprotozoan properties of new 3,5-disubstituted-tetrahydro-2H-1,3,5-thiadiazine-2-thione derivatives, Arznein Forsch, 49, 764
Oliveira DA, 1999, Evaluation of in vitro toxicity of N,N-dimethyl-2-propen-1-amines isomers, Pharmazie, 54, 847
Olmo E, 2001, Anti-Trypanosoma activity of some natural stilbenoids and synthetic related heterocyclic compounds, Bioorg Med Chem Lett, 11, 755, 10.1016/S0960-894X(01)00562-5
1998, Tratamiento Etiológico de la Enfermedad de Chagas: Conclusiones de una consulta técnica, Rev Patol Trop, 28, 247
Packchanian A, 1952, Chemotherapy of experimental Chagas disease with nitrofuran compounds, J Parasitol, 38, 30
Packchanian A, 1957, Chemotherapy of experimental Chagas disease with nitrofuran compounds, Antibiotics & Chemotherapy, 7, 13
Paglini-Oliva P, 1998, Structural, ultrastructural studies and evolution of Trypanosoma cruzi-infected mice treated with thioridazine, Exp Mol Pathol, 65, 78, 10.1006/exmp.1998.2227
Pereira DG, 1998, Activity of N,N-dimethyl-1-2-propen-1-amine derivatives in mice experimentally infected with Trypanosoma cruzi, Acta Trop, 69, 205, 10.1016/S0001-706X(97)00127-7
Pifano FC, 1941, La enfermedad de Chagas en el Estado Jaracuy, Venezuela, Caracas Medico, 8, 1103
Pineda JP, 1998, Comparison between classical and artificial xenodiagnosis in chronic Chagas disease, Rev Soc Bras Med Trop, 31, 473
Pinto AV, 1997, Trypanocidal activity of synthetic heterocyclic derivatives from active quinones from Tabebuia sp, Arzneim-Forsch, 4, 74
Polak A, 1978, Mode of action of 2-nitroimidazole derivative benznidazole, Ann Trop Med Parasitol, 72, 228, 10.1080/00034983.1978.11719278
Prata A, 1963, Estado atual da terapêutica da doença de Chagas: Revisão dos medicamentos até hoje utilizados, Rev Goiana Medicina 9, 109
Prata A, 1975, Tratamento da doença de Chagas pelo nifurtimox (Bayer 2505), Rev Soc Brasil Med Trop, 6, 297, 10.1590/S0037-86821975000600004
Rassi A, 1971, Tentativas de tratamento específico da fase aguda da doença de Chagas com nitrofuranos em esquemas de duração prolongada, Rev Soc Bras Med Trop, 5, 235, 10.1590/S0037-86821971000500001
Rassi A, 1992, Therapy of Chagas disease, 237
Rassi A, 1999, Protective effect of benznidazole against parasite reactivation in patients chronically infected with Trypanosoma cruzi and treated with corticoids for associated diseases, Rev Soc Bras Med Trop, 32, 475
Reche P, 1996, Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain, Mol Biochem Parasitol, 76, 175, 10.1016/0166-6851(95)02557-X
Rezende JM, 1959, Forma digestiva da moléstia de Chagas, Rev Goiana Med, 5, 193
Rezende JM, 1960, Aspectos clínicos e radiológicos da aperistalsis do esôfago, Rev Bras Gastroenterol, 12, 247
Richle R, 1973, Chemotherapy of experimental acute Chagas disease in mice: beneficial effect of Ro-71051 on parasitemia and tissue parasitism, Le Progres Medical, 101, 282
Rivarola HW, 1999, Thioridazine treatment modifies the evolution of Trypanosoma cruzi infection in mice, Ann Trop Med Parasitol, 93, 695, 10.1080/00034983.1999.11813474
Rivas P, 1999, Effects of some beta-carboline alkaloids on intact Trypanosoma cruzi epimastigotes, Comp Biochem Physiol C Pharmacol Toxicol Endocrinol, 122, 27, 10.1016/S0742-8413(98)10069-5
Rodrigues RR, 1995, Chelating agent inhibition of Trypanosoma cruzi epimastigotes in vitro, J Inorg Biochem, 60, 277, 10.1016/0162-0134(95)00027-5
Rodriguez JB, 2001, Specific molecular targets to control tropical diseases, Curr Pharm Des, 7, 1105, 10.2174/1381612013397555
Rodriguez JB, 1995, Recent developments in the control of Trypansoma cruzi, the causative agents of Chagas disease, Curr Med Chem, 2, 723, 10.2174/092986730203220224091158
Rodriguez JB, 2000, Sulphur-containing derivatives structurally related to fenoxycarb are potent growth inhibitors against the intracellular form of Trypanosoma cruzi, Int J Antimicrob Agents, 13, 215, 10.1016/S0924-8579(99)00125-9
Roush WR, 2000, Design, synthesis and evaluation of D-homophenylalanylepoxysuccinate inhibitors of the trypanosomal cystein protease cruzain, Tetrahedron, 56, 9747, 10.1016/S0040-4020(00)00882-6
Rovai LE, 1990, Effect of gossypol on trypomastigotes and amastigotes of Trypanosoma cruzi, J Protozool, 37, 280, 10.1111/j.1550-7408.1990.tb01148.x
Ryley JF, 1988, Activity of ICI 195,739 - a novel orally active bistriazole: in rodent models of fungal and protozoal infection, Ann N Y Acad Sci, 310, 328
Salmon-Chemin L, 2001, 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity, J Med Chem, 44, 548, 10.1021/jm001079l
Santa-Rita RM, 2000, Effect of alkyllysophospholipids on the proliferation and differentiation of Trypanosoma cruzi, Acta Trop, 75, 219, 10.1016/S0001-706X(00)00052-8
Santos AF, 2001, Molluscicidal and trypanocidal activities of lapachol derivatives, Planta Med, 67, 92, 10.1055/s-2001-10877
Schenone H, 1969, Experiência terapêutica con el Bayer 2502 en la infección chagasica cronica del adulto: Importancia del uso adequado del xenodiagnóstico, Bol Chil Parasitol, 24, 66
Schenone H, 1975, Atividade quimioterápica de um derivado nitroimidazolacetamida na infecção chagásica crônica, Bol Chil Parasitol, 30, 91
Schenone H, 1972, Treatment of chronic Chagas infection with Lampit, Bol Chil Parasitol, 27, 11
Schenone H, 1981, Estudio longitudinal de la persistencia de la acción terapéutica del nifurtimox y del benznidazol en pacientes con infección chagásica crónica, Bol Chil Parasitol, 36, 59
Schofield CJ, 1999, The Southern Cone Initiative against Chagas disease, Adv Parasitol, 42, 1, 10.1016/S0065-308X(08)60147-5
Schmeda-Hirschmann G, 2001, Cryptofolione derivatives from Cryptocarya alba fruits, J Pharm Pharmacol, 53, 563, 10.1211/0022357011775686
Schmunis GA, 1994, American trypanosomiasis as a public health problem, 3
Schmunis GA, 2000, A tripanosomíase americana e seu impacto na saúde pública das américas, 2, 1
Silva NN, 1974, Eficácia e tolerância do nitrofurfurilidene na fase crônica da moléstia de Chagas, Rev Soc Bras Med Trop, 88, 325, 10.1590/S0037-86821974000600003
Silveira JF, 1992, Trypanosoma cruzi recombinant antigens for serodiagnosis, 207
Silveira JF, 2001, Chagas disease: Recombinant Trypanosoma cruzi antigens for serological diagnosis, Trends in Parasitology, 17, 286, 10.1016/S1471-4922(01)01897-9
Singh PK, 1997, Synthesis and in vitro trypanocidal activity of some novel iron chelating agents, Arznein Forsch, 47, 311
Solari A, 1993, Successful treatment of Trypanosoma cruzi encephalitis in a patient with hemophilia and AIDS, Clin Inf Dis, 16, 255, 10.1093/clind/16.2.255
Sosa Estani S, 1998, Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease, Am J Trop Med Hyg, 59, 526, 10.4269/ajtmh.1998.59.526
Souza DH, 1998, Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design, FEBS Lett, 424, 131, 10.1016/S0014-5793(98)00154-9
Stoka V, 1995, Inhibition of cruzipain, the major cysteine proteinase of the protozoan parasite, Trypanosoma cruzi, by proteinase inhibitors of the cystatin superfamily, FEBS Lett, 370, 101, 10.1016/0014-5793(95)00798-E
Stoppani AOM, 1999, The chemotherapy of Chagas disease, Medicina (B Aires), 59, 147
Storino R, 1994, Tratamento antiparasitário específico, 557
Sturm NR, 1989, Sensitive detection by amplification of kinetoplast minicircle DNA sequences: use in diagnosis of Chagas disease, Mol Biochem Parasitol, 33, 205, 10.1016/0166-6851(89)90082-0
Sundar S, 1998, Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex, Ann Trop Med Parasitol, 92, 755, 10.1080/00034983.1998.11813337
Sundar S, 2000, Short-course of oral miltefosine for treatment of visceral leishmaniasis, Clin Infect Dis, 31, 1110, 10.1086/318122
Szajnman SH, 2000, Design and synthesis of aryloxyethyl thiocyanate derivatives as potent inhibitors of Trypanosoma cruzi proliferation, J Med Chem, 43, 1826, 10.1021/jm9905007
Tarleton RL, 2001, Parasite persistence in the aetiology of Chagas disease, Int J Parasitol, 31, 550, 10.1016/S0020-7519(01)00158-8
Teixeira AR, 1990, Chagas disease: lymphoma growth in rabbits treated with benznidazole, Am J Trop Med Hyg, 43, 146, 10.4269/ajtmh.1990.43.146
Teixeira AR, 1994, Chagas disease: carcinogenic activity of the antitrypanosomal nitroarenes in mice, Mutat Res, 305, 189, 10.1016/0027-5107(94)90239-9
Thomas SM, 1984, Crystal violet: a direct- acting frameshift mutagen whose mutagenicity is enhanced by mammalian metabolism, Mutation Res, 140, 165, 10.1016/0165-7992(84)90071-X
Tomazela DM, 2000, Pyrano chalcones and a flavone from Neoraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase-inhibitory activities, Phytochemistry, 55, 643, 10.1016/S0031-9422(00)00248-X
Tomimori-Yamashita J, 1997, Cutaneous manifestation of Chagas disease after heart transplantation: successful treatment with allopurinol, Br J Dermatol, 37, 626, 10.1111/j.1365-2133.1997.tb03800.x
Traub-Cseko YM, 2001, Dinitroaniline herbicides against protozoan parasites: the case of Trypanosoma cruzi, Trends Parasitol, 17, 136, 10.1016/S1471-4922(00)01834-1
Trouiller P, 2000, Pharmaceutical development concerning diseases predominating in tropical regions: The concept of indigent drugs, Ann Pharm Fr, 58, 43
Ullman B, 1997, Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates, Int J Parasitol, 27, 203, 10.1016/S0020-7519(96)00150-6
Umezawa ES, 1996, Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute and chronic Chagas disease, J Clin Microbiol, 37, 1554
Umezawa ES, 2001, Enzime-linked immunosorbent assay with Trypanosoma cruzi excreted-secreted antigens (TESA-ELISA) for serodiagnosis of acute and chronic Chagas' disease, Diag Microbiol Infect Disease, 39, 169, 10.1016/S0732-8893(01)00216-4
Urbina JA, 1999, Chemotherapy of Chagas disease: the how and the why, J Mol Med, 77, 332, 10.1007/s001090050359
Urbina JA, 1996, Cure of short- and long-term experimental Chagas disease using D0870, Science, 273, 969, 10.1126/science.273.5277.969
Urbina JA, 1999, Trypanosoma cruzi contains major pyrophosphate stores, and its growth in vitro and in vivo is blocked by pyrophosphate analogs, J Biol Chem, 274, 33609, 10.1074/jbc.274.47.33609
Urbina JA, 2000, In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi, Antimicrob Agents Chemother, 44, 2498, 10.1128/AAC.44.9.2498-2502.2000
Viotti R, 1994, Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up, Am Heart J, 127, 151, 10.1016/0002-8703(94)90521-5
Voller A, 1975, A micro-plate enzyme-linked immunosorbent assay (ELISA) for Chagas disease, The Lancet, 1, 426, 10.1016/S0140-6736(75)91492-0
Waechter AI, 1998, Leishmanicidal and trypanocidal activities of acetogenins isolated from Annona glauca, Phytotherapy Res, 12, 541, 10.1002/(SICI)1099-1573(199812)12:8<541::AID-PTR358>3.0.CO;2-5
Wang CC, 1997, Validating targets for antiparasite chemotherapy, Parasitology, 114, S31, 10.1017/S0031182097001017
Wendel S, 1992, Transfusion transmitted Chagas disease, 103
1984
1997
Wieder T, 1999, Mechanisms of action of phospholipid analogs as anticancer compounds, Prog Lipid Res, 38, 249, 10.1016/S0163-7827(99)00004-1
Winker P, 1994, Use of simplified polymerase chain reaction procedures to detect, Trypanosoma cruzi in blood samples from chronic chagasic patients in rural area, Am J Trop Med Hyg, 51, 771, 10.4269/ajtmh.1994.51.771
Yardley V, 1999, In vitro and in vivo activity of amphotericin B-lipid formulations against experimental Trypanosoma cruzi infections, Am J Trop Med Hyg, 61, 193, 10.4269/ajtmh.1999.61.193
Yong V, 2000, Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases, Mol Biochem Parasitol, 109, 47, 10.1016/S0166-6851(00)00237-1
Zaidenberg A, 1999, Effects of trifluralin on Trypanosoma cruzi in vitro and in vivo, Pharmacol Toxicol, 84, 98, 10.1111/j.1600-0773.1999.tb00881.x
Zuccotto F, 1999, The structure-based design and synthesis of selective inhibitors of Trypanosoma cruzi dihydrofolate reductase, Bioorg Med Chem Lett, 9, 1463, 10.1016/S0960-894X(99)00213-9